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Abstract
Background: Recently, high proportions (15.6%–98.7%) of intravenous drug users (IDUs) in China were found to be positive
for hepatitis C virus (HCV). Yunnan Province is located in southwestern China and borders one of the world’s most important
opium-producing regions, thus it is an important drug trafficking route to other regions of China.
Methodology/Principal Findings: Here, we assessed 100 HCV-positive plasma samples from IDUs who were enrolled
through the Kunming Center for Disease Control and Prevention in 2012. HCV C/E1 fragments were PCR-amplified and
sequenced. We identified eight HCV subtypes (1a, 1b, 3a, 3b, 6a, 6n, 6u and 6v), of which genotype 6 was most predominant
(frequency, 47%) followed by genotypes 3 (41%) and 1 (12%). HCV subtypes 6n (30%) and 3b (29%) were most common and
were identified in 59% of the IDUs. We compared HCV genotypes among IDUs in Yunnan Province with those from other
regions and found that the distribution patterns of HCV genotypes in Yunnan Province were similar to those in southern
China, but different from those in eastern China. However, the distribution patterns of HCV subtypes varied among Yunnan
Province and southern China, despite the shared similar genotypes. A comparison of the current data with those previously
reported showed that the frequency of HCV genotype 6 increased from 25% to 47% within 5 years, especially subtypes 6a
(5% to 15%) and 6n (11.2% to 30%). In contrast, the frequencies of subtypes 3b and 1b decreased by almost 50% within 5
years.
Conclusion/Significance: Our results provided further information to support the assertion that drug trafficking routes
influence HCV transmission patterns among IDUs in Yunnan Province. The frequency of HCV genotypes and subtypes
changed rapidly among IDUs in Yunnan Province and subtypes 6a and 6n may have originated in Vietnam and Myanmar,
respectively.
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Introduction
Hepatitis C virus (HCV) is considered a principal cause of
chronic liver disease, such as liver fibrosis, liver cirrhosis, and
hepatocellular carcinoma, and currently infects about 170 million
people worldwide [1,2]. HCV has a positive-sense RNA genome
and belongs to the genus Hepacivirus of the family Flaviviridae. At
present, HCV is only known to naturally infect humans [3].
Individuals at high-risk for HCV infection include and percuta-
neous and intravenous drug users (IDUs), those receiving
transfusion of blood products and hemodialysis, as well as those
who engage in unprotected sex with multiple sex partners [4]. In
China, intravenous drug use has become the predominant mode
of HCV transmission [5], and HCV genotypes 3 and 6 are the
most predominant genotypes and account for almost 70% of
infections among IDUs [6–12].
Yunnan Province is located in southwestern China and borders
on one of the world’s most important poppy (Papaver somniferum)
growing areas and opium producing bases (the ‘Golden Triangle,’
an area near the border of Laos, Myanmar and Thailand), and has
been an important transfer station and drug trafficking route from
the Golden Triangle to Yunnan Province and then to other
regions of China. In 2012, Zhou et al. reported the prevalence of
HIV, HCV, HBV and co-infection among IDUs. They also found
the association of these viruses with high risk intravenous drug use
behaviors in Yunnan Province and observed that a high
proportion (77.7%) of IDUs were HCV-positive. [13]
In 2008, Xia et al. [8] investigated the distribution of HCV
genotypes and subtypes among IDUs in Yunnan Province, and
found that HCV genotype 3 was most predominant, followed by
genotypes 6 and 1. In the present study, we assessed changes in
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HCV genotypes and subtypes among IDUs in Yunnan Province
during the last 5 years and determined which HCV genotypes and
subtypes were currently predominant among IDUs in Yunnan
Province. Our results provided insights into HCV distribution
patterns among IDUs in Yunnan Province and HCV transmission
to surrounding regions. In addition, we identified changes in HCV




All participants submitted written informed consent to partic-
ipate in the present study. The protocol was in accordance with
the Helsinki Declaration and was approved by the Institutional
Review Boards of the Institute of Medical Biology, Chinese
Academy of Medical Sciences & Peking Union Medical College,
and Kunming Center for Disease Control and Prevention.
Samples
Samples were collected from 100 IDUs who were positive for
HCV RNA and were enrolled at a drug rehabilitation center in
Yunnan Province from January to May 2012. Whole blood
samples (about 5 mL) were collected and immediately transported
to the Kunming Center for Disease Control and Prevention
(Kunming CDC) for detection of HCV antibodies and RNA.
Serological assays
HCV antibody analysis was performed at the Kunming CDC.
The presence of HCV antibodies was determined using an enzyme
immunoassay kit (Wantai Inc., Beijing, China and Zhuhai Livzon,
Inc., Zhuhai, China).
RNA extraction and reverse transcription polymerase
chain reaction ( RT-PCR) amplification
Total RNA was extracted from 200 uL of HCV-positive plasma
using the MiniBEST Viral RNA/DNA Extraction Kit Ver 4.0
(TaKaRa Biotechnology, Co., Ltd., Dalian, China) and comple-
mentary DNA (cDNA) was synthesized using the PrimeScript 1st
Strand cDNA Synthesis Kit (TaKaRa Biotechnology, Co., Ltd,
Dalian, China.). As reported previously [14], the PCR primers to
amplify the C/E1 regions of the HCV genome were W195 (59-
TTCATCATCATRTCCCANGCCAT-39) and W196 (59-
AAYYTDCCCGGTTGCTCTTTYTCTAT-39). Each 25-mL re-
action volume contained 3 mL of cDNA as a template, 2.5 mL of
106 ExTaq PCR buffer (TaKaRa Biotechnology, Co., Ltd,
Dalian, China.), 200 mM of each dNTP, 0.2 mM of each primer,
and 0.625 U of ExTaq polymerase. DNA amplification consisted
of 40 cycles at 54uC for 30 s, 72uC for 60 s, and 94uC for 30 s,
followed by a 5-min extension step at 72uC.
DNA purification, T-A cloning, and sequencing
Amplicons were purified using the Universal DNA Purification
kit (Tiangen Biotech Co., Ltd., Beijing, China) and then cloned
using the pMD19-T vector (TaKaRa Biotechnology Co. Ltd,
Dalian, China.). Positive plasmids were sequenced by the Beijing
Genomics Institute (Beijing, China).
HCV genotyping and phylogenetic analyses
The sequences of all samples were aligned with HCV subtype
reference sequences (C/E1 region) using the ClustalW multiple
sequence alignment tool included in the Molecular Evolutionary
Genetics Analysis (MEGA) v5.0 software package [15]. Reference
HCV subtype sequences were downloaded from GenBank
(accession numbers: EF115781.1, EF115784.1, EF115789.1,
EF115797.1, GQ379231.1, JX102829.1, FJ687119.1,
AY231591.1, JF721232.1, JF721240.1, JX102720.1, FJ210675.1,
GQ206071.1, JF721261.1, AY739386.1, JX183345.1,
JF721060.1, GQ205894.1, JF721029.1, JX183344.1,
JF721079.1, GQ206083.1, AY739416.1, JQ303368.1,
EU081433.1, FJ435090.1, and JQ318377.1). Phylogenetic trees
of the HCV C/E1 regions were constructed using MEGA 5.0
software with the neighbor-joining method [15], and the reliability
of the trees were evaluated using the bootstrap method with 1,000
replications
Statistical analysis
HCV genotype and subtype frequencies for the present study
were directly calculated and those from samples collected from
IDUs from other regions were obtained from previous studies, as
follows: Jiangsu Province [6,12], Guangxi Province [9], Guang-
dong Province [11], Myanmar [10], and Vietnam [16]. The
geographic distribution of IDUs from Yunnan Province and other
regions used for comparison is shown in Figure 1. Jiangsu Province
is located in eastern China, whereas Guangxi and Guangdong
Provinces are located in southern China. Myanmar and Vietnam
are located in Southeast Asia and border Guangxi and Yunnan
Provinces. Significant differences between the HCV genotype
frequencies among different regions were determined by a
contingency test using SPSS software (version 13.0; SPSS, Inc.,
Chicago, IL, USA). A probability (p) value,0.05 was considered
statistically significant.
Results
Prevalent HCV subtypes among IDUs in Yunnan Province
HCV C/E1 fragments were amplified successfully from all
HCV-positive samples. In the present study, three HCV genotypes
(1, 3 and 6) were identified, which included eight HCV subtypes
(1a, 1b, 3a, 3b, 6a, 6n, 6u and 6v). HCV genotype 6 was the most
predominant with a frequency of 47%, followed by genotype 3
(41%) and genotype 1 (12%). For HCV genotype 6, four subtypes
were observed, whose frequencies were 15% (subtype 6a), 30%
(subtype 6n) and 1% (subtype 6u and 6v, respectively). HCV
genotype 3 included two subtypes, 3a (frequency, 12%) and 3b
(frequency, 29%). HCV genotype 1 also included two subtypes, 1a
(frequency, 2%) and 1b (frequency, 10%), respectively. A
phylogenetic tree showing the relationship of the HCV C/E1
fragments is shown in Figure 2.
HCV genotype distribution among IDUs from Yunnan
Province and other regions
The frequencies of HCV genotypes among IDUs from different
regions were showed in Table 1 and Figure 1. HCV genotype 6
was the most prevalent genotype in Yunnan (frequency, 47%),
Guangxi (frequency, 46%) and Guangdong (frequency, 52%)
Provinces, which are all located in southern or southwestern
China. HCV genotype 6 was also common in Myanmar
(frequency, 49%). There were no significant differences among
the frequencies of HCV genotypes 1 and 3 in Yunnan, Guangxi,
and Guangdong Provinces and Myanmar (p.0.05). However,
there were significant differences among HCV genotypes 1 and 6
between Yunnan and Jiangsu Provinces, which are located in
eastern China (p,0.05). There were no significant differences in
the distribution of HCV genotype 3 between Yunnan and Jiangsu
Provinces (p.0.05). Interestingly, the distribution of all three HCV
genotypes showed statistically significant differences between
HCV Genotype Diversity among IDUs in Yunnan
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Yunnan Province and Vietnam (p,0.05), despite their shared
border.
Distribution of HCV genotypes and subtypes among
IDUs in the current study and a previous study
conducted in Yunnan Province
In 2008, Xia et al. [8] investigated the distribution of HCV
genotypes and subtypes among IDUs from Yunnan Province and
found that genotype 3 was most predominant, followed by
genotype 6 and genotype 1 (frequencies, 53.8%, 25% and
21.2%, respectively). Compared to the study by Xia et al., which
assessed HCV genotypes 1, 3 and 6, the frequency of HCV
genotype 6 significantly increased from 25% to 47% (p,0.05)
(Table 1). HCV subtype analysis showed changes in HCV subtype
frequencies: 1a, 1.2% to 2%; 1b, 20% to 10%; 3a, 23.8% to 12%;
3b, 30% to 29%; 6a, 5% to 15%; 6n, 11.2% to 30%; and 6u, 8.8%
to 1%. In the present study, subtypes 3a, 6a, 6n and 6u showed
different distribution patterns compared to a previous study
(p,0.05).
Discussion
Recently, several studies have reported an increase in HCV-
positive IDUs [17]. In China, at least three genotypes (1, 3 and 6)
and 11 subtypes (1a, 1b, 2a, 2b, 3a, 3b, 6a, 6n, 6u, 6v and 6e) were
observed among IDUs [17]. However, the distribution of HCV
genotypes and subtypes among IDUs differed between regions
[6,9–12,16,18]. Many studies have shown that the distribution of
HCV was similar to that found along the drug-trafficking routes
[6,11,17,19] In the present study, we investigated the prevalence
of HCV genotypes and subtypes in 100 IDUs from Yunnan
Province and confirmed the circulation of three HCV genotypes
(genotype 1, 3 and 6) and eight HCV subtypes (subtype 1a, 1b, 3a,
3b, 6a, 6n, 6u and 6v) (Tables 1).
A comparison of the HCV genotype and subtype distribution
patterns between our results and those of other studies showed
Figure 1. A map of Yunnan Province and other regions and HCV corresponding HCV distribution patterns.
doi:10.1371/journal.pone.0082598.g001
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differences between eastern and southern and southwestern China.
For example, HCV genotype 1 was most prevalent in Jiangsu
Province (frequencies, 24% and 28%, respectively); however, its
frequency was only 10% and 11% in southern and southwestern
China, respectively. In contrast, HCV genotype 6 was more
frequent in Yunnan Province and southern China (47% and 52%,
respectively) than eastern China (20% and 33%, respectively).
Next, we compared our results with those reported from Vietnam
and Myanmar, which both border Yunnan Province, and found
significant differences between Vietnam and Yunnan Province
(p,0.05) in the frequencies of genotype 1 (70% vs. 12%,
respectively), genotype 3 (2% vs. 41%, respectively), and genotype
6 (28% vs. 47%, respectively). In contrast, HCV distribution in
Myanmar was similar to that in Yunnan Province and other
southern and southwestern regions in China, including Guangxi
and Guangdong Provinces (p.0.05).
HCV genotype analysis showed that HCV genotype 6 was
predominant in southern and southwestern regions of China (46%
to 52%), although frequencies of other HCV of subtype 6 were
different among these regions. For example, the distribution
frequency of HCV subtype 6a was significantly greater in Guangxi
and Guangdong Provinces compared to Yunnan Province (46%
and 52% vs. 15%; p,0.05). In 2012, Fu et al. [11] proposed that
HCV subtype 6a originated in Vietnam and circulated to
neighboring regions, including Guangxi and Yunnan Provinces.
The different distribution frequencies of subtype 6a between
Guangxi and Yunnan Provinces may be explained by the drug
trafficking from Vietnam to Yunnan Province by way of Guangxi
Province, which has been identified as an important drug transfer
region. Surprisingly, HCV subtype 6a was not detected in samples
from Myanmar. In 2009, Pybus et al. demonstrated that HCV
subtype 6n may have originated in Thailand/Myanmar and has
since become predominant in Yunnan Province and Myanmar
[20], but was not detected in Guangxi and Guangdong Provinces
or Vietnam. The different distribution patterns of HCV subtypes
6a and 6n between Yunnan Province, Myanmar, and Vietnam
Figure 2. A phylogenetic tree estimated from C/E1 fragment
sequences corresponding to H77 (nucleotide positions, 843–
1315).
doi:10.1371/journal.pone.0082598.g002
Table 1. The frequencies (%) of HCV genotypes and subtypes within IDUs in current study and comparison with other in different
regions.
Yunnan Yunnan Guangxi Guangdong Jiangsu Jiangsu Vietnam Myanmar
(n = 100) (n = 80) Liuzhou(n = 96) Shanwei(n = 136) Suzhou(n = 85) Zhenjiang(n = 71) (n = 124) (n = 145)
Genotype 1 12 21.2 11 10 24 28 70 11
Subtype 1a 2 1.2 7 0 4 1 42 4.1
Subtype1b 10 20 4 10 20 27 28 6.9
Genotype 2 0 0 0 0 10 0 0 0.7
Subtype 2a 0 0 0 0 1 0 0 0.7
Genotype 3 41 53.8 35 33 41 52 2 39.3
Subtype 3a 12 23.8 20 31 14 38 1 9.6
Subtype 3b 29 30 15 2 27 14 1 29.7
Genotype 6 47 25 46 52 33 20 28 49
Subtype 6a 15 5 46 52 22 8.5 22.5 0
Subtype 6n 30 11.2 0 0 10 3 0 38.6
Subtype 6u 1 8.8 0 0 1 0 0 0
Subtype 6v 1 0 0 0 0 0 0 0
Subtype 6e 0 0 0 0 0 8.5 4 0
Subtype 6 h 0 0 0 0 0 0 1.5 9
Others 0 0 8 5 1 0 0 1.4
References This study Xia et al. Tan et al. Fu et al. Du et al. Zhang et al. Dunford et
al.
Lwin et al.
Note: the other means other genotype 6 and dual infection.
doi:10.1371/journal.pone.0082598.t001
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indicated that they may have originated in Vietnam and
Myanmar, respectively. HCV subtype 3b was also a common
HCV subtype in Yunnan Province. Its frequency in Yunnan
Province (29%) was similar to that in Myanmar (29.7%), but much
higher than in Vietnam (1%). The HCV subtype 3b may spread to
other eastern and southern regions of China, such as Jiangsu (14%
and 27%) and Guangxi Provinces (15%), via drug trafficking from
Yunnan Province and/or Myanmar, but not Vietnam
[6,9,10,12,16].
A comparison of our results with those of Xia [8] in 2008
showed no significant changes in the distribution of HCV
genotypes over the past 5 years. However, the frequency of
HCV subtypes 1b and 3a decreased from 20% to 10% and 23.8%
to 12%, respectively, whereas the frequency of HCV subtypes 6a
and 6n increased from 5% to 15% and 11.2% to 30%,
respectively. These results indicated that the increased frequency
of HCV subtypes 6a and 6n may have circulated along drug
trafficking routes from Myanmar and Vietnam and fueled the
increased distribution of subtype 6 among IDUs in Yunnan
Province.
Since the sample size of the IDUs in the present study was
relatively small, we were unable to provide a more comprehensive
scenario of HCV transmission in Yunnan Province. However, our
results provided further information to support the assertion that
this drug trafficking route has influenced the rate of HCV
transmission and changes in genotypes among IDUs in Yunnan
Province.
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